Stock Track | IDEXX Laboratories Soars 8.99% Intraday After Q2 Earnings Beat and Raised Full-Year Profit Forecast

Stock Track08-04

IDEXX Laboratories (IDXX) shares surged 8.99% during intraday trading on Tuesday, as investors reacted to the veterinary diagnostics company's better-than-expected second-quarter results and an upward revision to its annual profit outlook.

The company reported adjusted earnings per share of $4.27 for the quarter ended June 30, handily beating the consensus analyst estimate of $3.94. Revenue rose 10% year-over-year to $1.22 billion, also exceeding the $1.20 billion forecast. Robust demand for pet healthcare testing and higher diagnostic utilization at veterinary clinics drove the solid performance.

IDEXX raised its full-year 2026 earnings guidance to a range of $14.69 to $14.94 per share, up from $14.45 to $14.90 previously, with the new midpoint above Wall Street's $14.65 estimate. The company also narrowed its annual revenue forecast to $4.70 billion to $4.75 billion, lifting the midpoint slightly above consensus. The improved outlook reflects confidence in sustained growth across the Companion Animal Group and diagnostic recurring revenue streams.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184795845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184795845","market":"us","top_or_hot":-1,"title":"Stock Track | IDEXX Laboratories Soars 8.99% Intraday After Q2 Earnings Beat and Raised Full-Year Profit Forecast","media":"Stock Track","content":"<p>IDEXX Laboratories (IDXX) shares surged 8.99% during intraday trading on Tuesday, as investors reacted to the veterinary diagnostics company's better-than-expected second-quarter results and an upward revision to its annual profit outlook.</p><p>The company reported adjusted earnings per share of $4.27 for the quarter ended June 30, handily beating the consensus analyst estimate of $3.94. Revenue rose 10% year-over-year to $1.22 billion, also exceeding the $1.20 billion forecast. Robust demand for pet healthcare testing and higher diagnostic utilization at veterinary clinics drove the solid performance.</p><p>IDEXX raised its full-year 2026 earnings guidance to a range of $14.69 to $14.94 per share, up from $14.45 to $14.90 previously, with the new midpoint above Wall Street's $14.65 estimate. The company also narrowed its annual revenue forecast to $4.70 billion to $4.75 billion, lifting the midpoint slightly above consensus. The improved outlook reflects confidence in sustained growth across the Companion Animal Group and diagnostic recurring revenue streams.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IDEXX Laboratories Soars 8.99% Intraday After Q2 Earnings Beat and Raised Full-Year Profit Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IDEXX Laboratories Soars 8.99% Intraday After Q2 Earnings Beat and Raised Full-Year Profit Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-04 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IDEXX Laboratories (IDXX) shares surged 8.99% during intraday trading on Tuesday, as investors reacted to the veterinary diagnostics company's better-than-expected second-quarter results and an upward revision to its annual profit outlook.</p><p>The company reported adjusted earnings per share of $4.27 for the quarter ended June 30, handily beating the consensus analyst estimate of $3.94. Revenue rose 10% year-over-year to $1.22 billion, also exceeding the $1.20 billion forecast. Robust demand for pet healthcare testing and higher diagnostic utilization at veterinary clinics drove the solid performance.</p><p>IDEXX raised its full-year 2026 earnings guidance to a range of $14.69 to $14.94 per share, up from $14.45 to $14.90 previously, with the new midpoint above Wall Street's $14.65 estimate. The company also narrowed its annual revenue forecast to $4.70 billion to $4.75 billion, lifting the midpoint slightly above consensus. The improved outlook reflects confidence in sustained growth across the Companion Animal Group and diagnostic recurring revenue streams.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDXX","symbol_name":"爱德士实验室","start_time":0,"source_url":"","article_id":"1184795845","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184795845","pubTimestamp":1785850918,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IDEXX Laboratories (IDXX) shares surged 8.99% during intraday trading on Tuesday, as investors reacted to the veterinary diagnostics company's better-than-expected second-quarter results and an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDXX":"爱德士实验室"},"translate_title":"股票跟踪 | IDEXX Laboratories 第二季度盈利超出预期并上调全年利润预期后盘中飙升 8.99%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDXX":1},"content_text":"IDEXX Laboratories (IDXX) shares surged 8.99% during intraday trading on Tuesday, as investors reacted to the veterinary diagnostics company's better-than-expected second-quarter results and an upward revision to its annual profit outlook.The company reported adjusted earnings per share of $4.27 for the quarter ended June 30, handily beating the consensus analyst estimate of $3.94. Revenue rose 10% year-over-year to $1.22 billion, also exceeding the $1.20 billion forecast. Robust demand for pet healthcare testing and higher diagnostic utilization at veterinary clinics drove the solid performance.IDEXX raised its full-year 2026 earnings guidance to a range of $14.69 to $14.94 per share, up from $14.45 to $14.90 previously, with the new midpoint above Wall Street's $14.65 estimate. The company also narrowed its annual revenue forecast to $4.70 billion to $4.75 billion, lifting the midpoint slightly above consensus. The improved outlook reflects confidence in sustained growth across the Companion Animal Group and diagnostic recurring revenue streams.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184795845","isCrawlerRequest":true}